Inventor · disambiguated record
Ekaterina V. Breous-Nystrom
Also filed as: BREOUS-NYSTROM EKATERINA V · BREOUS-NYSTROM EKATERINA VLADIMIROVNA
14 granted patents·11 pending applications·62 citations·filing 2016–2023
91Inventor score
Top patents by PatentIndex Score
25 records- 0197US10836830B2Antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Nov 17, 2020·12 cites·45 claims
- 0296US10639368B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 5, 2020·15 cites·32 claims
- 0396US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0495US10912828B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·4 cites·36 claims
- 0595US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 0685US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 0785US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 0884US11447557B2Antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Sep 20, 2022·3 cites·46 claims
- 0984US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 1084US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 1184US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 1282US2024181048A1Anti-tim-3 antibodies and methods of use thereofAGENUS INC·Filed 2023·Application pending·0 cites
- 1380US11359028B2Anti-OX40 antibodies and anti-GITR antibodiesAGENUS INC·Filed 2019·Granted Jun 14, 2022·1 cites·16 claims
- 1480US2023406946A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 1580US2023399413A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 1679US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 1776US11718658B2T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereofMINK THERAPEUTICS INC·Filed 2020·Granted Aug 8, 2023·1 cites·21 claims
- 1875US12011481B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Jun 18, 2024·0 cites·28 claims
- 1973US2022389107A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2073US2022380479A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2172US2021171648A1Antibodies and methods of use thereofAGENUS INC·Filed 2020·Application pending·0 cites
- 2271US11839653B2Anti-TIM-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Dec 12, 2023·0 cites·25 claims
- 2370US12391741B2T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereofMINK THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·20 claims
- 2467US2021324097A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 2555US2020079862A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →